Search
Levocarnitine
go.drugbank.com/drugs/DB00583ApprovedInvestigationalConstituent of striated muscle and liver. It is used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias.
Mixtures: BEAUTIFUL CONTRACT - Slimming contract -Hui Ju Sheng Enterprise Corporation Ltd.Ribavirin
go.drugbank.com/drugs/DB00811ApprovedInvestigationalProducing a broad-spectrum activity against several RNA and DNA viruses, Ribavirin is a synthetic guanosine nucleoside and antiviral agent that interferes with the synthesis of viral mRNA. It is primarily indicated for use in treating he...
Mixtures: Rebetron Ready To Use Solution (albumin(human)free) (6000000 Iu/ml and 200mg Capsules)Benzonatate
go.drugbank.com/drugs/DB00868ApprovedBenzonatate was approved by the FDA in 1958 under the market name Tessalon Perles.
Chloroprocaine
go.drugbank.com/drugs/DB01161ApprovedInvestigational[A252952,L43382] Topical chloroprocaine for ophthalmic use was approved by the FDA in September 2022 for ocular surface anesthesia.[L43387]
Sevoflurane
go.drugbank.com/drugs/DB01236ApprovedInvestigationalVet approved[L42340] Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996.
Dapagliflozin
go.drugbank.com/drugs/DB06292ApprovedInvestigational[A261601] Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise.
Products: Nra-dapagliflozinLebrikizumab
go.drugbank.com/drugs/DB11914ApprovedInvestigational[L49404] Lebrikizumab was also approved by the FDA on September 13, 2024.[L51379]
Bexagliflozin
go.drugbank.com/drugs/DB12236ApprovedInvestigational[A256423,L44758] In January 2023, bexagliflozin was approved by the FDA for the treatment of adults with type 2 diabetes.
Linaclotide
go.drugbank.com/drugs/DB08890ApprovedInvestigationalLinaclotide was first approved by the FDA on August 30, 2012.[A260271] It gained EMA and Health Canada approval on November 26, 2012 [L47216] and December 3, 2013,[L47221] respectively.
Idarucizumab
go.drugbank.com/drugs/DB09264ApprovedApproved under the tradename Praxbind (FDA), idarucizumab is indicated for the emergency treatment of dabigatran-associated bleeding in life-threatening or surgically induced situations.